奥希替尼在T790M阳性晚期NSCLC中的中枢神经系统疗效:AURA3随机III期试验
AURA3 III期试验纳入419例T790M阳性晚期NSCLC患者,随机2:1接受奥希替尼80mg每日一次或铂类-培美曲塞。预设亚组分析显示,在可测量CNS病灶患者中,奥希替尼CNS客观缓解率显著优于化疗(70% vs 31%),CNS无进展生存期也显著延长(11.7 vs 5.6个月)。
要点
- 奥希替尼在可测量CNS病灶患者中CNS ORR达70%,显著高于铂类-培美曲塞的31%。
- 奥希替尼组中位CNS PFS为11.7个月,化疗组为5.6个月,HR 0.32。
- 无症状稳定CNS转移患者可入组,奥希替尼显示出优越的中枢神经系统疗效。
核心结论
- 在T790M阳性晚期NSCLC患者中,奥希替尼相比铂类-培美曲塞显示出更优的中枢神经系统疗效。
研究设计与样本
- AURA3是一项随机III期试验,纳入419例既往EGFR-TKI治疗后进展的T790M阳性晚期NSCLC患者,随机2:1接受奥希替尼80mg每日一次或铂类-培美曲塞。
- 预设亚组分析纳入基线脑扫描显示可测量和/或不可测量CNS病灶的患者,由盲法独立中心神经影像学审查评估。
主要发现
- 可测量和/或不可测量CNS病灶患者中,奥希替尼组中位CNS缓解持续时间为8.9个月(95%CI 4.3个月-不可计算),化疗组为5.7个月(95%CI 4.4-5.7个月)。
临床怎么用
- 对于既往EGFR-TKI治疗后进展的T790M阳性晚期NSCLC伴无症状稳定CNS转移患者,奥希替尼可考虑作为优先治疗选择。
局限性
- CNS可评估缓解集仅包括具有一个或多个可测量CNS病灶的患者,样本量较小。
- 研究仅纳入无症状且稳定的CNS转移患者,结果不能外推至有症状或不稳定CNS转移患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose In patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), there is an unmet need for EGFR-tyrosine kinase inhibitors with improved CNS penetration and activity against CNS metastases, either at initial diagnosis or time of progression. We report the first comparative evidence of osimertinib CNS efficacy versus platinum-pemetrexed from a phase III study (AURA3; ClinicalTrials.gov identifier: NCT02151981) in patients with EGFR T790M-positive advanced NSCLC who experience disease progression with prior EGFR-tyrosine kinase inhibitor treatment. Methods Patients with asymptomatic, stable CNS metastases were eligible for enrollment and were randomly assigned 2:1 to osimertinib 80 mg once daily or platinum-pemetrexed. A preplanned subgroup analysis was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiological review. The CNS evaluable for response set included only patients with one or more measurable CNS lesions. The primary objective for this analysis was CNS objective response rate (ORR). Results Of 419 patients randomly assigned to treatment, 116 had measurable and/or nonmeasurable CNS lesions, including 46 patients with measurable CNS lesions. At data cutoff (April 15, 2016), CNS ORR in patients with one or more measurable CNS lesions was 70% (21 of 30; 95% CI, 51% to 85%) with osimertinib and 31% (5 of 16; 95% CI, 11% to 59%) with platinum-pemetrexed (odds ratio, 5.13; 95% CI, 1.44 to 20.64; P = .015); the ORR was 40% (30 of 75; 95% CI, 29% to 52%) and 17% (7 of 41; 95% CI, 7% to 32%), respectively, in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 3.24; 95% CI, 1.33 to 8.81; P = .014). Median CNS duration of response in patients with measurable and/or nonmeasurable CNS lesions was 8.9 months (95% CI, 4.3 months to not calculable) for osimertinib and 5.7 months (95% CI, 4.4 to 5.7 months) for platinum-pemetrexed; median CNS progression-free survival was 11.7 months and 5.6 months, respectively (hazard ratio, 0.32; 95% CI, 0.15 to 0.69; P = .004). Conclusion Osimertinib demonstrated superior CNS efficacy versus platinum-pemetrexed in T790M-positive advanced NSCLC.
引用
- Wu YL, Ahn MJ, Garassino MC, et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018. PMID: 30059262. doi:10.1200/JCO.2018.77.9363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。